Picture of Nykode Therapeutics ASA logo

NYKD — Nykode Therapeutics ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Brief: Vaccibody Enters Into Worldwide License Agreement With Adaptive Biotechnologies

July 12 (Reuters) - Vaccibody AS  VACC-ME.OL :
    * VACCIBODY ENTERS INTO WORLDWIDE LICENSE AGREEMENT WITH
ADAPTIVE
    * VACCIBODY AND ADAPTIVE BIOTECHNOLOGIES HAVE ENTERED INTO
EXCLUSIVE AGREEMENT FOR USE OF ADAPTIVE'S VALIDATED SARS-COV-2 T
CELL EPITOPES
    * VACCIBODY WILL USE SELECTED SET OF THESE SARS-COV-2 T CELL
EPITOPES IN ITS SECOND-GENERATION SARS-COV-2 VACCINE TRIAL,
PLANNED FOR Q4 2021

Source text for Eikon:  ID:nObiVfwMVa 
Further company coverage:  VACC-ME.OL 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Nykode Therapeutics ASA

See all news